fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Lomustine (ccnu)

All products: general benefit

CeeNU · DIN 00360414 · 100 mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-01 — choose a marketed DIN from the same-category list.Discontinued October 1, 2019 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2019-10-01 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
CeeNU · DIN 00360414 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2019-10-01 · brand CEENU · ATC L01AD02 LOMUSTINE · form Capsule · route Oral · ingredients LOMUSTINE 100 MG · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

CeeNU: Formulary list price $22.46 per unit (the source does not state the unit; exact figure $22.4550). What the ministry pays, not the patient.

Ministry pays: $22.4550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00360414)

Source record
DIN 00360414: CeeNU Raw flags: sec3=Y Item: 100000042; group id 171; item number 0302; lccId None; manufacturer id BQU Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $22.4550; ministry $22.4550 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00360414 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2529
Shortage status: discontinued (September 30, 2019, reported by BRISTOL-MYERS SQUIBB CANADA) · Tier 3; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00360414
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 1, 2019 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (L01A): coverage varies; not interchangeable

  • Busulfan (Myleran): general benefit
  • Chlorambucil (Leukeran): general benefit
  • Cyclophosphamide (Procytox): general benefit, not a benefit
  • Melphalan (Alkeran): general benefit
  • Temozolomide (Temodal): general benefit
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab

MELPHALAN

· 1 products · General benefit · strengths: 2mg · Tab

TEMOZOLOMIDE

· 20 products · General benefit · strengths: 5mg, 20mg, 100mg, 140mg, 250mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USES CeeNU (lomustine-CCNU) is indicated as palliative therapy in addition to surgery and radiotherapy or in combination therapy with other chemotherapeutic agents in the following: 1. Brain tumors - both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures. 2. Hodgkin's Disease – as a secondary therapy, alone or in combination with other active drugs. Other Tumors – CeeNU has been used in combination with other therapeutic agents in lung cancer (squamous cell, anaplastic large cell, and adenocarcinoma), malignant melanoma and breast cancer (advanced disease) only after other conventional methods have failed. https://pdf.hres.ca/dpd_pm/00085229.PDF PM date: JUN 29, 2026 Source product: CEENU; DIN 00360422; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

CeeNU · DIN 00360414 Shortage status: discontinued (2019-09-30, reported by BRISTOL-MYERS SQUIBB CANADA) · Tier 3; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00360414

Check this DIN again